This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Commission unveils details on plan for phasing out animaltesting for chemicals safety At the REACH and CLP regulators’ meeting in July, the European Commission revealed specifics about its formal schedule to eliminate animaltesting used for chemical safety assessment.
Commission redoubles commitment to reduce animaltesting in response to Citizens’ Initiative The European Commission provided its mandatory response to a citizens’ petition this week urging faster action to reduce and ultimately eliminate animaltesting within the cosmetics and chemical sectors.
5,6 The range of CNS-related toxicities encountered throughout drug development and post-market approval is vast, and includes abuse liability, suicidal ideation, emesis, sleep disorder and cognitive dysfunction to name a few. 2009 Sep;14(17–18):876–84. Neurotoxicology. 2010 Aug;31(4):331–50. Drug Discov Today. Toxicol In Vitro.
The PPPR framework governs the authorization, sale, and use of PPPs, establishing a pre-market approval process for active substances – the pesticide components which control pests, weeds, and plant diseases – and for synergists and safeners before they can be allowed for use in PPPs.
EU court upholds ban on chlorpyrifos-methyl, setting regulatory precedent in the process The General Court of the European Union this week upheld the non-renewal of market authorization for chlorpyrifos-methyl used as an active substance in pesticides. It also found this approach beneficial because it reduces the need for animaltesting.
This also has clear potential to reduce animaltesting, another key commitment made by the Commission. An observatory will also be created that publicly compiles information on the properties, uses, and market presence of certain chemicals. This observatory will initially focus on nanomaterials.
The earliest patent I found was issued in late 2009, for “Products and Methods for Reducing Malodor from the Pudendum.” ” But, tellingly, “Neither the law nor FDA regulations require specific tests to demonstrate the safety of individual products or ingredients.” ” Lady parts. Remember the statins?
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content